Lucentis in DME: so far so good

Article

Ranibizumab (Lucentis; Novartis) is an effective treatment for diabetic macular oedema (DME), according to Peter Campochiaro, MD, from the Department of Ophthalmology, Wilmer Eye Institute, USA, speaking at the Retina Subspecialty Day.

Ranibizumab (Lucentis; Novartis) is an effective treatment for diabetic macular oedema (DME), according to Peter Campochiaro, MD, from the Department of Ophthalmology, Wilmer Eye Institute, USA, speaking at the Retina Subspecialty Day.

Twenty patients with chronic macular oedema were enrolled in a Phase I trial. Inclusion criteria included a foveal thickness of 250 microns or greater, vision of 20/40 to 20/320, no laser treatment during the previous three months, no periocular or intraocular steroids for four months or anti-angiogenic treatment for 12 months. The study design called for an intravitreal injection of 0.5 mg of ranibizumab at baseline and at one, two, four and six months. The primary end-point was month seven and the patients were followed for one year.

Dr Campochiaro used the the optical coherence tomography scans of two patients to demonstrate the results. "The response to ranibizumab was rapid," he reported. "One week after the first injection, there was marked improvement in the foveal thickening. In one patient the improvement remained for the duration of the trial; in the second patient, there was an initial improvement one week after injection, but the improvement deteriorated over one and two months with the development of substantial macular oedema."

All twenty patients responded to ranibizumab, but the pattern of the response differed among patients. The improvement in the mean excess foveal thickness at the primary end point was about 87%, an improvement that Dr Campochiaro described as "dramatic."

Even one year after treatment, there was still substantial improvement in the foveal thickness. At the primary end point, the median improvement in foveal thickness was 300 microns, a 97% improvement. The mean improvement in visual acuity was 10 letters.

"Six months after the last treatment, there was still significant improvement compared with baseline, raising the following questions: What is the appropriate interval for the injections? What are the long-term effects of the treatment? Is there any benefit to combining this treatment with laser treatment?" Dr Campochiaro posed.

A Phase II trial is planned.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.